{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:27:45Z","timestamp":1764937665461,"version":"3.41.2"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:00:00Z","timestamp":1705276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The prognostic role of Wilms\u2019 tumor 1 (WT1) gene expression at diagnosis in children with B cell precursor acute lymphoblastic leukemia (BCP-ALL) is still controversial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We detected the WT1 transcript levels of 533 <jats:italic>de novo<\/jats:italic> pediatric BCP-ALL patients using TaqMan-based real-time quantitative PCR and analyzed their clinical features.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The WT1 transcript levels differed among the distinct molecularly defined groups, with the highest levels in the <jats:italic>KMT2A<\/jats:italic> rearrangements (<jats:italic>KMT2A-r<\/jats:italic>) group. According to the results of the X-tile software, all patients were divided into two groups: WT1\/ABL \u2265 0.24% (group A) and &amp;lt;0.24% (group B). The proportions of patients whose age was \u226510 years old, with immunophenotype of Pro-B, belonging in high-risk group, or with minimal residual disease (MRD) \u2265 0.01% at week 12 were significantly higher in group A than in group B. In the B-other group, WT1 overexpression was an independent risk factor of overall survival (OS) rate (<jats:italic>P<\/jats:italic> = 0.042), and higher MRD \u2265 0.01% at week 12 was associated with lower OS rate (<jats:italic>P<\/jats:italic>&amp;lt;0.001) and event-free survival rate (<jats:italic>P<\/jats:italic>&amp;lt;0.001). Moreover, the subgroup analysis revealed that, in patients with initial WBC&amp;lt;50 \u00d7 10<jats:sup>9<\/jats:sup>\/L or MRD&amp;lt;0.1% at day 33 or MRD&amp;lt;0.01% at week 12 or in the standard-risk group, WT1 overexpression led to a poorer outcome in comparison with those with WT1 downexpression (<jats:italic>P<\/jats:italic>&amp;lt;0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Therefore, pediatric BCP-ALL with WT1 overexpression had unique clinico-pathological characteristics and poor treatment response. In B-other patients, WT1 overexpression at diagnosis predicted an inferior prognosis. The WT1 gene may serve as a biomarker for monitoring residual disease in the B-other population, especially in children in the standard-risk group.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1297870","type":"journal-article","created":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T04:21:29Z","timestamp":1705292489000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic significance of Wilms\u2019 tumor gene 1 expression in children with B-cell precursor acute lymphoblastic leukemia"],"prefix":"10.3389","volume":"13","author":[{"given":"Yu-juan","family":"Xue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Le-ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai-dong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue-ping","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-xi","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-min","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.6004\/jnccn.2020.0001","article-title":"Pediatric acute lymphoblastic leukemia, version 2.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Brown","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.247031","article-title":"Pediatric acute lymphoblastic leukemia","volume":"105","author":"Inaba","year":"2020","journal-title":"Haematologica"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03789-6","article-title":"The prognostic significance of Wilms' tumor gene 1 (WT1) expression at diagnosis in adults with Ph-negative B cell precursor acute lymphoblastic leukemia","volume":"98","author":"Qin","year":"2019","journal-title":"Ann Hematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2020.1735670","article-title":"WT1 overexpression predicted good outcomes in adult B-cell acute lymphoblastic leukemia patients receiving chemotherapy","volume":"25","author":"Wang","year":"2020","journal-title":"Hematology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-015-0002-0","article-title":"WT1 expression in adult acute myeloid leukemia: assessing its presence, magnitude and temporal changes as prognostic factors","volume":"22","author":"Ujj","year":"2016","journal-title":"Pathol Oncol Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.632094","article-title":"Wilms tumor 1 mutations are independent poor prognostic factors in pediatric acute myeloid leukemia","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2016.008","article-title":"Prognostic impact of WT-1 gene expression in Egyptian children with acute lymphoblastic leukemia","volume":"8","author":"Hagag","year":"2016","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-020-03063-w","article-title":"The role of minimal residual disease in specific subtypes of pediatric acute lymphoblastic leukemia","volume":"113","author":"Xue","year":"2021","journal-title":"Int J Hematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1733-1","article-title":"Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity","volume":"92","author":"Zhao","year":"2013","journal-title":"Ann Hematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.596677","article-title":"Re-emergence of minimal residual disease detected by flow cytometry predicts an adverse outcome in pediatric acute lymphoblastic leukemia","volume":"10","author":"Wang","year":"2020","journal-title":"Front Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404047","article-title":"Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring","volume":"20","author":"Boublikova","year":"2006","journal-title":"Leukemia"},{"key":"B12","article-title":"Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia","volume":"19","author":"Zhang","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0713","article-title":"X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization","volume":"10","author":"Camp","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404624","article-title":"A tumor suppressor and oncogene: the WT1 story","volume":"21","author":"Yang","year":"2007","journal-title":"Leukemia"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.806804","article-title":"The many facets of WT1 in acute myeloid leukemia: clarity remains elusive","volume":"55","author":"Marlton","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404924","article-title":"Deregulation of the Wilms' tumour gene 1 protein (WT1) by BCR\/ABL1 mediates resistance to imatinib in human leukaemia cells","volume":"21","author":"Svensson","year":"2007","journal-title":"Leukemia"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2012.578","article-title":"WT1 silencing by RNAi synergizes with chemotherapeutic agents and induces chemosensitization to doxorubicin and cisplatin in B16F10 murine melanoma cells","volume":"3","author":"Zapata-Benavides","year":"2012","journal-title":"Oncol Lett"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.170431","article-title":"WT1 loss attenuates the TP53-induced DNA damage response in T-cell acute lymphoblastic leukemia[J]","volume":"103","author":"Bordin","year":"2018","journal-title":"Haematologica"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1297870\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T04:21:32Z","timestamp":1705292492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1297870\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,15]]},"references-count":18,"alternative-id":["10.3389\/fonc.2023.1297870"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1297870","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2024,1,15]]},"article-number":"1297870"}}